Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Sangart Announces Closing of $50 Million Series G Financing

April 19, 2011 By Bio-Medicine.Org

SAN DIEGO, April 19, 2011 /PRNewswire/ — Sangart, Inc., today
announced that it recently received more than $50 million in new
equity funding from existing investors, led by Leucadia National
Corporation. The most recent investment brings the total funding
raised by the company since its inception in 1998 to more than $230
million. This financing round also included warrants which, if
exercised, could provide up to an additional $50 million in future
funding.

Funds raised in this Series G round will be used to advance the
development of the MP4OX product in severe traumatic hemorrhage and
the MP4CO product in sickle cell disease. MP4OX is an
investigational biopharmaceutical designed to enhance the perfusion
of oxygen-deprived (ischemic) tissues and provide targeted oxygen
delivery in the capillaries. MP4CO is an investigational
biopharmaceutical designed to deliver therapeutic levels of carbon
monoxide (CO) to patients suffering from a sickle cell crisis.

“We are encouraged by this level of support from our existing
investors, who recognize the clinical potential of our products,”
said Brian O’Callaghan, President and CEO of Sangart. “This funding
will allow us to continue advancing the development of our
medicines and get them as quickly as possible to patients in need.
We continue to see promise in our MP4-based medicines in the
treatment of patients who experience an acute traumatic injury and
in patients with sickle cell disease suffering from a
vaso-occlusive crisis.”

About MP4Sangart’s product platform is based on the MP4
molecule, an investigational biopharmaceutical product designed to
enhance the perfusion of oxygen-deprived (ischemic) tissues and
provide targeted oxygen delivery in the capillaries. Using a novel
pegylation approach, Sangart produces the MP4 molecule designed at
the optimal oxygen affinity, diffusion potential and molecular size
to perfuse capillaries and target oxygen delivery to tissues
specifically at risk of

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech